Marengo Therapeutics has presented data at ESMO and SITC showing that its lead program, which is designed to activate Vβ6/10 T cells, is active in multiple tumor types

ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs

ASCO 2026: "The results that we presented from the RASolute 302 trial are unprecedented." - The CEO behind this year's pancreatic cancer breakthrough walks us through the full results and implications

London based Cytospire Therapeutics has announced an $83M series A financing to develop first-in-class pan-gamma delta T-cell engagers - the lead program is an EGFR targeting solid tumors

Replimune's Chairman discusses FDA's polarizing decision to not approve the company's melanoma treatment after a new review. He says they have filed a FOIA request to learn more about FDA's process

Invivyd develops monoclonal antibodies to prevent or treat infectious diseases. This approach could be useful in tamping down the measles outbreaks that have been occurring due to under-vaccination

Bay Area based Epia Neuro exited stealth earlier this month with the goal of developing a device implanted in the skull that could act as an interface to a glove to helps stroke survivors regain grip

Peter Hotez discusses tropical disease, the importance of science communication, career advice for young scientists, and more

Physican and Biotech Investor Adam May reacts to this morning's 52 week Rezpeg data in alopecia from Nektar

10x Genomics today is announcing Atera, its new in situ spatial transcriptomics platform

Is this analyst the world's biggest bear on the weight loss space? After downgrading Lilly to a sell rating, HSBC's Rajesh Kumar discusses why he thinks pricing factors are being under-appreciated